Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dialysis01:27

Dialysis

1.5K
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
1.5K
Dialysis01:15

Dialysis

1.8K
Dialysis is a diffusion-based purification process that separates analyte molecules from a complex matrix. This is accomplished by allowing molecules in the solution to pass through a semipermeable membrane into a liquid on the other side. The membrane is usually made of cellulose acetate or cellulose nitrate, and the second liquid must be miscible with the solution. Ions (e.g., chloride or sodium) or organic molecules (e.g., glucose) can pass through the membrane pores, which generally have...
1.8K
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

799
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
799
Peritoneal Dialysis I: Introduction and Procedure01:30

Peritoneal Dialysis I: Introduction and Procedure

3.2K
Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...
3.2K
Peritoneal Dialysis III: Nursing Management01:25

Peritoneal Dialysis III: Nursing Management

831
Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
831
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis01:30

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

520
Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
520

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

Bone marrow transplantation·2026
Same author

Unsolved Issues in Managing CKD-Associated Osteoporosis: Myths, Facts, and Clinical Grey Zones.

Kidney360·2026
Same author

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same author

Mesotherapy in Pain Management in Primary Care: A Narrative Review and Practice-Oriented Appraisal.

La Clinica terapeutica·2026
Same author

A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remission.

Bone marrow transplantation·2026
Same author

Mogamulizumab as Bridge to Thiotepa-Based Allogeneic Haematopoietic Stem Cell Transplantation in Sézary Syndrome: A Single-Centre Experience.

EJHaem·2026

Related Experiment Video

Updated: Feb 5, 2026

Manufacturing Of Robust Natural Fiber Preforms Utilizing Bacterial Cellulose as Binder
10:47

Manufacturing Of Robust Natural Fiber Preforms Utilizing Bacterial Cellulose as Binder

Published on: May 22, 2014

28.1K

[Hyperphosphatemia in dialysis: which binder?]

Carlo Alfieri1, Fabio Malberti2, Sandro Mazzaferro3

  • 1Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico Milano, Università degli Studi di Milano.

Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia
|September 21, 2018
PubMed
Summary
This summary is machine-generated.

High phosphorus levels in dialysis patients are linked to adverse events. New phosphate binders like sucroferric oxyhydroxide offer improved efficacy and reduced pill burden, enhancing patient compliance.

Keywords:
BinderPhosphateSecondary Hyperparathyroidism

More Related Videos

Method to Produce Durable Pellets at Lower Energy Consumption Using High Moisture Corn Stover and a Corn Starch Binder in a Flat Die Pellet Mill
08:52

Method to Produce Durable Pellets at Lower Energy Consumption Using High Moisture Corn Stover and a Corn Starch Binder in a Flat Die Pellet Mill

Published on: June 15, 2016

21.7K
A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

3.2K

Related Experiment Videos

Last Updated: Feb 5, 2026

Manufacturing Of Robust Natural Fiber Preforms Utilizing Bacterial Cellulose as Binder
10:47

Manufacturing Of Robust Natural Fiber Preforms Utilizing Bacterial Cellulose as Binder

Published on: May 22, 2014

28.1K
Method to Produce Durable Pellets at Lower Energy Consumption Using High Moisture Corn Stover and a Corn Starch Binder in a Flat Die Pellet Mill
08:52

Method to Produce Durable Pellets at Lower Energy Consumption Using High Moisture Corn Stover and a Corn Starch Binder in a Flat Die Pellet Mill

Published on: June 15, 2016

21.7K
A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

3.2K

Area of Science:

  • Nephrology
  • Clinical Pharmacology

Background:

  • Elevated serum phosphorus is associated with adverse outcomes in dialysis patients.
  • K-DIGO guidelines recommend normalizing phosphate levels through diet, dialysis optimization, and phosphate binders.
  • Current phosphate binders present challenges in achieving ideal efficacy, pill burden, side effects, and cost.

Purpose of the Study:

  • To evaluate the role of sucroferric oxyhydroxide as a novel phosphate binder.
  • To assess its efficacy in reducing pill burden and improving phosphorus control.
  • To investigate its safety profile, particularly gastrointestinal side effects.

Main Methods:

  • Review of randomized controlled trials evaluating sucroferric oxyhydroxide.
  • Analysis of data on phosphate binding capability and pill burden.
  • Examination of reported adverse events, focusing on gastrointestinal side effects.

Main Results:

  • Sucroferric oxyhydroxide demonstrates high phosphate binding capability, allowing for a lower daily pill count.
  • Clinical trials confirm its efficacy in managing hyperphosphatemia.
  • Gastrointestinal side effects have been noted in trials, with ongoing studies to assess real-world incidence.

Conclusions:

  • Sucroferric oxyhydroxide offers a promising option for managing hyperphosphatemia in dialysis patients due to its reduced pill burden.
  • High patient compliance may be improved with this novel binder.
  • Further real-world data is needed to fully characterize its safety profile.